In the perioperative context, the balance between thrombosis (in case of anticoagulation interruption) and bleeding (in case of anticoagulation continuation) should be assessed for each patient [ 43].
In the perioperative setting, these patients pose considerable challenges to physicians, who must weigh the thrombotic risks of therapy interruption against the bleeding risks of continuation.
DAPT cessation-modes were defined as physician-recommended discontinuation, temporary interruption, and disruption due to bleeding or poor compliance.
DAPT cessation modes were classified as temporary interruption (<14 days), disruption because of bleeding or poor compliance, and physician-recommended discontinuation.
In patients undergoing cardiac surgery with a negative history of bleeding and early interruption of antiplatelet treatment, the BT and platelet function do not offer much in the setting to predict perioperative bleeding.
"The Mystery Is in the Ordinary, Uncool Things" - An Interview with Author Juliet Escoria .
Use of bridging anticoagulation was associated with an increased risk of bleeding and adverse events after interruption.
Also, a bleeding event could have led to interruption of combination antithrombotic therapy, and thus to a higher risk of stent thrombosis.
Bridging anticoagulation is used in one quarter of anticoagulation interruptions and is associated with higher risk for bleeding and adverse events.
Bleeding was considered a reason for unsatisfactory dialysis when leading to premature interruption of the hemodialysis session or in case of major bleeding.
Therefore, interruption of antiplatelet therapy is not recommended in the absence of bleeding [23].
